New hope for lung cancer patients: high-dose drug combo tested after first treatment fails
Disease control
Recruiting now
This study tests two higher doses of the drug furmonertinib, either alone or combined with chemotherapy, in 60 people with advanced EGFR-mutant non-small cell lung cancer whose disease got worse after initial treatment with a similar drug. The goal is to see if these options can …
Phase: PHASE2 • Sponsor: Jialei Wang • Aim: Disease control
Last updated May 01, 2026 15:59 UTC